While some heterogeneity in apoptotic response was observed between cell lines and BP-CML patient samples, the combination of BCL-xL and BCR::ABL1 inhibition was consistently effective in inducing substantial apoptosis. Here, BCL2L1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.